Bank of New Hampshire Sells 1,645 Bristol-Myers Squibb (NYSE:BMY) Shares

Bank of New Hampshire trimmed its stake in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 12.9% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 11,097 shares of the biopharmaceutical company’s stock after selling 1,645 shares during the quarter. Bank of New Hampshire’s holdings in Bristol-Myers Squibb were worth $602,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of BMY. First National Bank of Mount Dora Trust Investment Services bought a new position in Bristol-Myers Squibb in the first quarter worth about $279,000. Walker Asset Management LLC boosted its stake in Bristol-Myers Squibb by 7.5% in the first quarter. Walker Asset Management LLC now owns 6,457 shares of the biopharmaceutical company’s stock valued at $350,000 after purchasing an additional 450 shares during the last quarter. Banque Cantonale Vaudoise boosted its holdings in Bristol-Myers Squibb by 35.1% in the first quarter. Banque Cantonale Vaudoise now owns 144,909 shares of the biopharmaceutical company’s stock worth $7,858,000 after buying an additional 37,663 shares during the period. Legacy Private Trust Co. raised its stake in Bristol-Myers Squibb by 3.5% in the first quarter. Legacy Private Trust Co. now owns 11,679 shares of the biopharmaceutical company’s stock valued at $633,000 after buying an additional 400 shares in the last quarter. Finally, Bruce G. Allen Investments LLC boosted its holdings in Bristol-Myers Squibb by 26.6% in the first quarter. Bruce G. Allen Investments LLC now owns 3,485 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 732 shares during the period. Hedge funds and other institutional investors own 76.41% of the company’s shares.

Bristol-Myers Squibb trading rose 2.2%

NYSE BMY opened at $41.93 on Friday. The company has a current ratio of 1.11, a quick ratio of 0.99, and a debt-to-equity ratio of 2.99. The stock has a 50-day moving average of $43.60 and a 200-day moving average of $48.45. The firm has a market cap of $85.00 billion, a PE ratio of -13.53, a price-to-earnings-growth ratio of 13.82 and a beta of 0.43. Bristol-Myers Squibb has a 1-year low of $39.63 and a 1-year high of $65.85.

Bristol-Myers Squibb (NYSE:BMY – Get Your Free Report ) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.53) by $0.13. The firm had revenue of $11.87 billion for the quarter, compared to analysts’ expectations of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The company’s revenue increased by 4.7% year-on-year. In the same quarter last year, the company earned $2.05 per share. As a group, sell-side analysts predict that Bristol-Myers Squibb will post 0.59 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Friday, July 5th will be given a dividend of $0.60 per share. This represents a dividend of $2.40 on an annualized basis and a yield of 5.72%. The ex-dividend date of this dividend is Friday, July 5. Bristol-Myers Squibb’s payout ratio is -77.42%.

Changes in Analyst Ratings

BMY has been the subject of several recent research reports. Societe Generale lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. Wells Fargo & Company lifted their target price on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a report on Thursday, April 18th. BMO Capital Markets cut their target price on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a report on Friday, April 26th. StockNews.com lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday, June 17th. Finally, Barclays cut their price target on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a report on Friday, April 26th . One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $60.00, according to MarketBeat.

Check out our latest research report on BMY

Bristol-Myers Squibb Company Profile

(Free report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic and neuroscience. The company’s products include Eliquis for reducing the risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anticancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Featured Articles

Want to see what other hedge funds BMY owns? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Free Report).

Get news and reviews for Bristol-Myers Squibb Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bristol-Myers Squibb and related companies with MarketBeat.com’s FREE daily email newsletter.